Treatment of the myeloproliferative disorders with 32 P
نویسندگان
چکیده
منابع مشابه
32P in the treatment of myeloproliferative disorders
UNLABELLED (32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the role of (32)P has been diminished. Today, Polycythaemia Rubra Vera (PRV) and Essential Th...
متن کاملRespiratory disorders associated with stroke and the role of physiotherapy in the treatment of these disorders
Introduction Stroke is a common neurological disease that can have a negative effect on all parts of the body. The respiratory system is one of the parts of the body that may be damaged by stroke. The respiratory disorders caused by stroke can occur in all three sections of the breath; including metabolic respiration, behavioral respiration and emotional respiration. Disorder in each of these ...
متن کاملMyeloproliferative disorders and its associated mutations
Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorde...
متن کاملCommentary (Haire): Diagnosis and Treatment of Thrombocythemia in Myeloproliferative Disorders
Dr. Gilbert has succinctly summarized much of the recently published literature on the diagnosis and treatment of thrombocytosis caused by polycythemia vera and essential thrombocythemia. Many of her recommendations reflect the opinions of most investigators and practitioners in the field. However, there is a body of literature and interpretations of cited studies that are not included in her a...
متن کاملDiagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Myeloproliferative disorders originate in the clonal expansion of a transformed pluripotential hematopoietic progenitor cell. This results in a group of syndromes that include polycythemia vera, essential thrombocythemia, chronic myelocytic leukemia, and agnogenic myeloid metaplasia. Diagnostic criteria forpolycythemia vera and essential thrombocythemia were codified by the Polycythemia Vera St...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Haematology
سال: 2000
ISSN: 0902-4441
DOI: 10.1034/j.1600-0609.2000.9r119.x